

**IS INTERIM PET OF CLINICAL VALUE
IN LYMPHOMAS OTHER THAN HL AND
DLBCL?
OR
CLINICAL CONSEQUENCES FROM
AND EARLY RESPONSE SCAN?**

Hagenbeek

Low grade malignant lymphomas

Follicular, NHL, grades I-3A

SLL

MZL/MALT

CLL

No clinical consequences given biology

Very aggressive lymphomas

Lymphoblastic

Burkitt

Not much to escalate after interim
PET (+) scan

NB Scanty data/collection of end of tx PET data

Currently ongoing interim PET studies in:

- MCL (European studies)
- PMBCL (Israel abstract B114)
- T-cell lymphomas
(Japan/B107; Korea B110)

Ultimate question:

Will interim PET lead to improved treatment outcome?